Figure 7
From: Identification of pharmacological agents that induce HMGB1 release
HMGB1 increases in mice plasma post IP injection of HMGB1 releasing agents. Female C57BL/6 mice (4 mice/group) were intraperitoneally administrated with suberoylanilide hydroxamic acid (SAHA) (100 mg/Kg), azacitidine (AZA) (50 mg/Kg), decitabine (DECI) (100 mg/Kg), oxaliplatin (OXA) (10 mg/Kg), fenbendazole (FENB) (200 mg/Kg) and oxibendazole (OXIB) (200 mg/Kg). Blood samples were collected at the indicated time points post injection (p.i.) and plasma was prepared as described in material and methods. Plasma HMGB1 levels were measured by means of a HMGB1-specific ELISA kit according to the manufacture protocol. Boxplots report the lower and upper quartile plus the median value. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (two-way ANOVA analysis).
